News Related to Congenital Adrenal Hyperplasia

Related coverage linked through entity extraction aliases.

Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations

Aug 11, 2026

Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.

Crinetics Reports Strong Early Sales for PALSONIFY, Positive Phase 2 Data for CAH Treatment

Feb 26, 2026

Crinetics Pharmaceuticals reported over $5 million in preliminary net product revenue for PALSONIFY in Q4 2025, while Phase 2 data for its congenital adrenal hyperplasia treatment showed promising results that analysts say have derisked the Phase 3 study design.